Description | This product is a human monoclonal antibody that reacts with FLT1. The antibody is expressed with mammalian cell transient expression system, serum-free and purified by affinity chromatography. The purity and integrity are tested via SDS-PAGE and SEC-HPLC analysis. Given an antigen, additional QC measures are also desired such as affinity testing and binding validation. Specifically, the antibody is provided in multiple formats for in vivo and in vitro assays. The Invivo version features greater than 95% purity, ultra-low endotoxin levels (<1 EU/mg or 0.1 EU/mg), and is preservative, stabilizer, and carrier protein-free. |
Clonality | Monoclonal |
Host Species | Human |
Target Species | Human |
Immunogen | Recombinant human soluble extracellular Flt-1 Ig-like loop 1 to 5 (sFlt-1(D5)). |
Epitope | Ig-like loops 1-5 of extracellular domain. |
Isotype | IgG |
Expression Species | HEK293F or CHO |
Conjugation | None |
Purity | >95%, determined by SDS-PAGE and/or SEC-HPLC |
Endotoxin | <1 EU/mg, determined by LAL method |
Purification | Protein A affinity purified |
Sterility | 0.2 μM filtered |
Formulation | PBS, pH 7.4 |
Preservation | No preservatives |
Stabilizer | No stabilizers |
Storage | Store at 4⁰C within a week. For longer storage, aliquot and store at -20⁰C. |
Application | DB; IF; IP; Neut; FuncS; ELISA; FC; WB |
Application Notes | The antibody is recommended for detection of FLT1 by IF, IP, Neut, FuncS, ELISA, FC, WB assays. |
ELISA | Enzyme-Linked Immunosorbent Assay Protocol |
WB | Western Blot Protocol |
FC | Flow Cytometry Protocol |
Target | FLT1 |
Alternative Name | FLT1; fms-related tyrosine kinase 1 (vascular endothelial growth factor/vascular permeability factor receptor); FLT; vascular endothelial growth factor receptor 1; VEGFR1; FLT-1; VEGFR-1; fms-like tyrosine kinase 1; tyrosin |
Gene ID | 2321 |
UniProt | P17948 |
Research Area | Cardiovascular; Signal Pathway |
Figure 1 Anti-VEGFR-1 Monoclonal Antibody (V3S-0622-YC4468) in ELISA
ELISA analysis of V3S-0622-YC4468 was performed by coating with human VEGFR-1 protein (His tag). Then blocked with BSA and incubated with V3S-0622-YC4468. The HRP-conjugated goat anti- human IgG as a secondary antibody (1: 2000). Detection was performed using TMB substrate and stopped with sulfuric acid. The absorbances were read on a spectrophotometer at 450 nm.
Figure 1 Anti-VEGFR-1 Monoclonal Antibody (V3S-0622-YC4468) in ELISA
Figure 2 Anti-VEGFR-1 Monoclonal Antibody (V3S-0622-YC4468) in WB
Western blot analysis of V3S-0622-YC4468 was performed by loading human VEGFR-1 protein (Lane 1 0.1 μg, Lane 2 0.3 μg, Lane 3 0.6 μg) onto a 12% Tris-HCl polyacrylamide gel. Proteins were transferred to a CN membrane and blocked with 5% skim milk for at least one hour. Membranes were probed with V3S-0622-YC4468 and HRP goat anti-human IgG (H+L) as a secondary antibody (1: 3000). Chemiluminescent detection was performed.
Figure 2 Anti-VEGFR-1 Monoclonal Antibody (V3S-0622-YC4468) in WB
Figure 3 Anti-VEGFR-1 Monoclonal Antibody (V3S-0622-YC4468) in DB
Dot Blot analysis of V3S-0622-YC4468 was performed by coating with human VEGFR-1 protein (His tag).
V3S-0622-YC4468 incubation concentration: 2 μg/mL.
HRP-conjugated goat anti-human IgG (H+L) as a secondary antibody (1: 3000)
NC: Negative control, PC: Positive control
Figure 3 Anti-VEGFR-1 Monoclonal Antibody (V3S-0622-YC4468) in DB